Drug intelligence / Profile preview

AMG 108

Development stage: Phase 2
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous, Intraarticular

Overview

AMG 108 is a fully human monoclonal antibody of the immunoglobulin G2 (IgG2) subclass that targets and binds to the human interleukin-1 receptor type 1 (IL-1R1), thereby inhibiting the activity of both interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β). By blocking IL-1 signaling, it was developed as an anti-inflammatory biologic for diseases such as rheumatoid arthritis and osteoarthritis. Clinical studies showed moderate symptomatic improvement in these conditions, but minimal clinical benefit overall. The drug was investigated primarily by Amgen[3][6][8].

Other names: MEDI8968MEDI-8968MEDI 8968AMG-108AMG108AMG 108Anti-IL-1R MAbAnti-IL1R MAbAnti-IL 1R MAb

Targets

IL1R1 (Interleukin-1 Receptor Type 1)

Beyond the preview

Go deeper on AMG 108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 108.

Explore the full profile